Stay updated on Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page has been updated to version 2.16.5, and the previous version 2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest has been deleted.
    Difference
    0.9%
    Check dated 2025-07-04T04:19:03.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.7%
    Check dated 2025-06-19T20:15:08.000Z thumbnail image
  4. Check
    23 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:25:36.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, and API users can provide input before this change. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T06:12:21.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The web page has been updated to include more precise eligibility criteria for subjects in a clinical study involving Nivolumab, including specific laboratory values and age requirements. Additionally, the text has been revised to clarify the exclusion criteria for certain patient populations.
    Difference
    35%
    Check dated 2025-04-30T18:47:39.000Z thumbnail image
  8. Check
    80 days ago
    Change Detected
    Summary
    The webpage has undergone significant content removal, particularly regarding the detailed background and objectives of a study on Nivolumab for treating Epstein-Barr Virus-related lymphoproliferative disorders. The revision number has also been updated from v2.14.4 to v2.15.0.
    Difference
    55%
    Check dated 2025-04-16T13:17:42.000Z thumbnail image

Stay in the know with updates to Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.